Europe’s latest recreational cannabis trial program is set to begin in Basel, Switzerland, this summer.
The program will involve only about 400 people, who will be able to buy recreational cannabis products from certain pharmacies.
However, the participants will be “questioned regularly” throughout the study about their mental and physical health.
The cannabis will be produced by Swiss-based Pure Production.
The lower house of Switzerland’s Federal Assembly first approved a bill for the trial program two years ago.
Experts have called the Swiss program an important milestone while also symbolic of the sluggish pace at which recreational legalization is occurring in Europe.
Europe often turns to “trial programs” for medical and recreational cannabis instead of full legalization and regulation.
The programs are often mired in delays and bureaucracy.
Business leaders need reliable industry data and in-depth analysis to make smart investments and informed decisions in these uncertain economic times.
Order your 2022 MJBiz Factbook, out now!
- 200+ pages and 50 charts with key data points
- State-by-state guide to regulations, taxes & opportunities
- Segmented research reports for the marijuana + hemp industries
- Accurate financial forecasts + investment trends
Stay ahead of the curve and avoid costly missteps in the rapidly evolving cannabis industry.
The latest example is the Dutch pilot program to allow the limited cultivation and distribution of recreational cannabis, which has been hit with another major delay.
The Dutch program is now expected to start in 2023.